Northwest Biotherapeutics (NWBO) Assets Average (2011 - 2026)

Northwest Biotherapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $80.7 million for Q1 2026.

• In Q1 2026, Assets Average rose 197.5% year-over-year to $80.7 million; the TTM figure through Mar 2026 stood at $80.7 million (up 197.5% YoY), while the FY2025 annual figure was $54.0 million, up 97.86% from the prior year.
• Assets Average for Q1 2026 stood at $80.7 million, up from $55.9 million in the prior quarter.
• The five-year high for Assets Average was $80.7 million in Q1 2026, with the low at $27.1 million in Q1 2025.
• The 5-year median for Assets Average is $29.7 million (2023), against an average of $34.3 million.
• The sharpest annual moves came in 2024 and 2026: Assets Average declined 12.09% in 2024, then jumped 197.5% in 2026.
• Northwest Biotherapeutics' Assets Average stood at $31.2 million in 2022, then declined by 4.91% to $29.7 million in 2023, then fell by 5.57% to $28.0 million in 2024, then jumped by 99.64% to $55.9 million in 2025, then jumped by 44.18% to $80.7 million in 2026.
• Business Quant data shows NWBO's Assets Average at $80.7 million in Q1 2026, $55.9 million in Q4 2025, and $30.1 million in Q3 2025.